Human islet amyloid polypeptide (hIAPP) aggregation in type 2 diabetes: Correlation between intrinsic physicochemical properties of hIAPP aggregates and their cytotoxicity

2019 ◽  
Vol 136 ◽  
pp. 57-65 ◽  
Author(s):  
Ali Chaari ◽  
Moncef Ladjimi
PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0149409 ◽  
Author(s):  
Paola C. Rosas ◽  
Ganachari M. Nagaraja ◽  
Punit Kaur ◽  
Alexander Panossian ◽  
Georg Wickman ◽  
...  

2017 ◽  
Vol 74 (15) ◽  
pp. 2827-2838 ◽  
Author(s):  
Gema Alcarraz-Vizán ◽  
Carlos Castaño ◽  
Montse Visa ◽  
Joel Montane ◽  
Joan-Marc Servitja ◽  
...  

2016 ◽  
Vol 55 (20) ◽  
pp. 10727-10740 ◽  
Author(s):  
Carolina Sánchez-López ◽  
Rodrigo Cortés-Mejía ◽  
Marco C. Miotto ◽  
Andres Binolfi ◽  
Claudio O. Fernández ◽  
...  

2008 ◽  
Vol 2008 ◽  
pp. 1-8 ◽  
Author(s):  
J. W. M. Höppener ◽  
H. M. Jacobs ◽  
N. Wierup ◽  
G. Sotthewes ◽  
M. Sprong ◽  
...  

Human islet amyloid polypeptide (hIAPP), a pancreatic islet protein of 37 amino acids, is the main component of islet amyloid, seen at autopsy in patients with type 2 diabetes mellitus (DM2). To investigate the roles of hIAPP and islet amyloid in DM2, we generated transgenic mice expressing hIAPP in their islet beta cells. In this study, we found that after a long-term, high-fat diet challenge islet amyloid was observed in only 4 of 19 hIAPP transgenic mice. hIAPP transgenic females exhibited severe glucose intolerance, which was associated with a downregulation of GLUT-2 mRNA expression. In isolated islets from hIAPP males cultured for 3 weeks on high-glucose medium, the percentage of amyloid containing islets increased from 5.5% to 70%. This ex vivo system will allow a more rapid, convenient, and specific study of factors influencing islet amyloidosis as well as of therapeutic strategies to interfere with this pathological process.


Sign in / Sign up

Export Citation Format

Share Document